R. Zaczek

发表

Excitatory amino acid analogues: Neurotoxicity and seizures

J. Coyle, R. Zaczek, 1982, Neuropharmacology.

Development of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor Agonists.

M. D. Hill, J. Macor, Yulia Benitex, 2017, ACS medicinal chemistry letters.

Effects of repeated fenfluramine administration on indices of monoamine function in rat brain: pharmacokinetic, dose response, regional specificity and time course data.

J. Contrera, E. D. De Souza, G. Battaglia, 1990, The Journal of pharmacology and experimental therapeutics.

Kainic acid: insights from a neurotoxin into the pathophysiology of Huntington's disease.

J. Coyle, J. Ferkany, R. Zaczek, 1983, Neurobehavioral toxicology and teratology.

The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist.

G. Trainor, A. Cocuzza, D. Robertson, 2000, Bioorganic & medicinal chemistry.

Solubilization of high affinity corticotropin-releasing factor receptors from rat brain: characterization of an active digitonin-solubilized receptor complex.

E. D. De Souza, D. Grigoriadis, R. Zaczek, 1989, Endocrinology.

A Glutamate N-Methyl-d-Aspartate (NMDA) Receptor Subunit 2B–Selective Inhibitor of NMDA Receptor Function with Enhanced Potency at Acidic pH and Oral Bioavailability for Clinical Use

R. Dingledine, D. Liotta, S. Traynelis, 2021, The Journal of Pharmacology and Experimental Therapeutics.

Kainic acid neurotoxicity and seizures

J. Coyle, R. Zaczek, M. Nelson, 1981, Neuropharmacology.

Dopamine transporter: expression in Xenopus oocytes.

G. Uhl, B. O’Hara, T. Nishimori, 1991, Brain research. Molecular brain research.

Methylphenidate and pemoline do not cause depletion of rat brain monoamine markers similar to that observed with methamphetamine.

J. Contrera, E. D. De Souza, G. Battaglia, 1989, Toxicology and applied pharmacology.

Cerebrospinal fluid homovanillic acid and parkinsonism in Huntington's disease

K. Jeffries, I. Shoulson, R. Kurlan, 1988, Annals of neurology.

Dihydropyridopyrazinones and dihydropteridinones as corticotropin-releasing factor-1 receptor antagonists: structure-activity relationships and computational modeling.

G. Trainor, T. Molski, M. Rafalski, 2007, Journal of medicinal chemistry.

N‐Acetyl‐Aspartyl‐Glutamate: Regional Levels in Rat Brain and the Effects of Brain Lesions as Determined by a New HPLC Method

J. Coyle, K. Koller, R. Zaczek, 1984, Journal of neurochemistry.

Interactions of Acidic Peptides: Excitatory Amino Acid Receptors

J. Coyle, R. Fisher, D. Carpenter, 1986 .

Characterization of [125I]sauvagine binding to CRH2 receptors: membrane homogenate and autoradiographic studies.

B. Largent, D. Rominger, R. Grzanna, 1998, The Journal of pharmacology and experimental therapeutics.

Interactions of [3H]amphetamine with rat brain synaptosomes. II. Active transport.

E. D. De Souza, R. Zaczek, S. Culp, 1991, The Journal of pharmacology and experimental therapeutics.

Interactions of [3H]amphetamine with rat brain synaptosomes. I. Saturable sequestration.

E. D. De Souza, D. Mccann, R. Zaczek, 1991, The Journal of pharmacology and experimental therapeutics.

Pharmacological Characterization of a Novel Nonpeptide Antagonist Radioligand, (±)-N-[2-Methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for Corticotropin-Releasing Factor1 Receptors

D. Rominger, C. Rominger, Xiao-Xin Yan, 2003, Journal of Pharmacology and Experimental Therapeutics.

Effects of linopirdine, HP 749, and glycyl‐prolyl‐glutamate on transmitter release and uptake

C. Teleha, S. Tam, R. Zaczek, 1993 .

Unique properties of norepinephrine release from terminals arising from the locus coeruleus: high potassium sensitivity and lack of linopirdine (DuP 996) enhancement

S. Tam, R. Zaczek, W. J. Tinker, 1993, Neuroscience Letters.

Cerebrospinal fluid correlates of depression in Huntington's disease.

J. Coyle, C. Nemeroff, I. Shoulson, 1988, Archives of neurology.

In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.

Vijay T. Ahuja, J. Macor, H. Wong, 2009, Journal of medicinal chemistry.

Signal Peptide Peptidase and γ-Secretase Share Equivalent Inhibitor Binding Pharmacology*

J. Corradi, C. Albright, R. Olson, 2007, Journal of Biological Chemistry.

Glutamate-containing dipeptides enhance specific binding at glutamate receptors and inhibit specific binding at kainate receptors in rat brain

J. Coyle, J. Ferkany, R. Zaczek, 1984, Neuroscience Letters.

Preclinical Evaluation of Linopirdine: Neurochemical and Behavioral Effects

K. Rohrbach, S. Tam, R. Zaczek, 1995 .

4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.

S. Shelton, G. Trainor, P. Hartig, 2000, Journal of medicinal chemistry.

2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action.

R. Earl, C. Teleha, S. Tam, 1998, Journal of medicinal chemistry.

Differential effects of DSP-4 on noradrenaline axons in cerebral cortex and hypothalamus may reflect heterogeneity of noradrenaline uptake sites

J. Fritschy, R. Grzanna, R. Zaczek, 1990, Brain Research.

Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine.

R. Earl, D. Rominger, M. Pierdomenico, 1998, The Journal of pharmacology and experimental therapeutics.

[3H]WIN 35,065–2: A Ligand for Cocaine Receptors in Striatum

M. Kuhar, D. Grigoriadis, F. Carroll, 1990, Journal of Neurochemistry.

Effects of anaesthetics and anticonvulsants on the action of kainic acid in the rat hippocampus.

J. Coyle, R. Zaczek, M. Nelson, 1978, European journal of pharmacology.

CHANGING RELATIONSHIPS AMONG NEUROTRANSMITTER SYSTEMS IN DEVELOPING STRIATUM: IMPLICATIONS FOR NEURO-PSYCHOPHARMACOLOGY

P. Campochiaro, J. Coyle, R. Zaczek, 1978 .

Linopirdine. A depolarization-activated releaser of transmitters for treatment of dementia.

S. Tam, R. Zaczek, 1995, Advances in experimental medicine and biology.

Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice.

C. Albright, R. Olson, J. Toyn, 2007, The Journal of pharmacology and experimental therapeutics.

Regional Distribution to Recovery of 5‐HT Levels after Administration of “Atrophins” MDMA and D, L‐Fenfluramine Stereospecificity and Comparison with 5,7‐Dihydroxytryptamine

J. Lehmann, E. Desouza, R. Zaczek, 1992, Annals of the New York Academy of Sciences.

Failure of folic acid derivatives to mimic the actions of kainic acid in brain in vitro or in vivo.

J. Coyle, J. Ferkany, J. Slevin, 1982, Neurobehavioral toxicology and teratology.

Neuronal receptor sites for kainic acid: correlations with neurotoxicity.

J. Coyle, J. Slevin, R. Zaczek, 1981, Advances in biochemical psychopharmacology.

A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist.

Vijay T. Ahuja, J. Macor, Y. Shu, 2009, Journal of medicinal chemistry.

Kainic Acid: Neurotoxicity and Receptor Interactions

J. Coyle, K. Bizière, J. Slevin, 1982 .

Kainic acid stimulates excitatory amino acid neurotransmitter release at presynaptic receptors

J. Coyle, J. Ferkany, R. Zaczek, 1982, Nature.

The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists.

H. Wong, M. D. Lindner, N. Lodge, 2006, CNS drug reviews.

Design, Synthesis, and Biological Evaluation of 1,2,3,7-Tetrahydro-6H-purin-6-one and 3,7-Dihydro-1H-purine-2,6-dione Derivatives as Corticotropin-Releasing Factor1 Receptor Antagonists

Vijay T. Ahuja, K. K. Nanda, G. Trainor, 2004 .

Purin-8-ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists.

G. Trainor, L. Fitzgerald, R. Zaczek, 1999, Bioorganic & medicinal chemistry letters.

Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.

C. Hodge, Y. Wong, F. Hobbs, 1999, Journal of medicinal chemistry.

Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists.

J. Macor, G. Trainor, H. Wong, 2012, Bioorganic & medicinal chemistry letters.

2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action.

R. Earl, C. Teleha, S. Tam, 1998, Journal of medicinal chemistry.

Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.

J. Macor, Shuang Liu, T. Molski, 2014, ACS medicinal chemistry letters.

Linopirdine: Pharmacology of a Neurotransmitter Release Enhancer

B. S. Brown, R. Zaczek, R. J. Chorvat, 1997 .

Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain

Alan G. E. Wilson, G. Shankar, S. Mandlekar, 2016, The Journal of Pharmacology and Experimental Therapeutics.

γ-Secretase Inhibitors for Alzheimer’s Disease

C. Albright, D. Barten, J. Meredith, 2006 .

Memory-Enhancing Drugs

R. Zaczek, R. J. Chorvat, 2000 .

Binding Sites of γ-Secretase Inhibitors in Rodent Brain: Distribution, Postnatal Development, and Effect of Deafferentation

P. Wong, R. Olson, C. Rominger, 2004, The Journal of Neuroscience.

Anxiolytic-Like Effects of the Corticotropin-Releasing Factor1 (CRF1) Antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] Administered Acutely or Chronically at Doses Occupying Central CRF1 Receptors in Rats

S. Arneric, G. Trainor, R. Taub, 2004, Journal of Pharmacology and Experimental Therapeutics.

Anxiolytic-Like Effects of the Corticotropin-Releasing Factor 1 ( CRF 1 ) Antagonist DMP 904 [ 4-( 3-pentylamino )-2 , 7-dimethyl-8-( 2-methyl-4-methoxyphenyl )-pyrazolo-[ 1 , 5-a ]-pyrimidine ] Administered Acutely or Chronically at Doses Occupying Central CRF 1 Receptors in Rats

S. Arneric, G. Trainor, R. Taub, 2004 .

Anxiolytic-like Effects of the CRF1 Antagonist DMP904 Administered Acutely or Chronically at Doses Occupying Central CRF1 Receptors in Rats

S. Arneric, R. Taub, H. Wong, 2003 .

Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder

Aiqing He, John P. Corradi, George Tseng, 2014, Molecular Psychiatry.

Long-term sequelae of striatal kainate lesion

J. Coyle, R. Schwarcz, R. Zaczek, 1978, Brain Research.

Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancy

M. Seager, J. Macor, S. Gerritz, 2016, Neuropharmacology.

Microinjection of kainic acid into the rat hippocampus.

J. Coyle, R. Schwarcz, R. Zaczek, 1978, European journal of pharmacology.

MDMA Effects in Brain: Pharmacologic Profile and Evidence of Neurotoxicity from Neurochemical and Autoradiographic Studies

G. Battaglia, R. Zaczek, E. Souza, 1990 .

Chapter 5. Corticotropin-Releasing Hormone (CRH) Receptors and the Discovery of Selective Non-Peptide CRH1 Antagonists

D. Robertson, P. Hartig, R. Zaczek, 1997 .

Clinical symptomatology, CSF neurotransmitter metabolites, and serum haloperidol levels in Tourette syndrome.

J. Coyle, H. Singer, L. Tune, 1982, Advances in neurology.

Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.

S. Arneric, G. Trainor, H. Wong, 2009, Journal of medicinal chemistry.

Design and synthesis of a novel series of 4-heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes as α7 nicotinic receptor agonists 2. Development of 4-heteroaryl SAR.

M. D. Hill, J. Macor, Yulia Benitex, 2017, Bioorganic & medicinal chemistry letters.

BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.

J. Macor, Yulia Benitex, D. Post‐Munson, 2017, ACS medicinal chemistry letters.

Comparison of the effects of repeated oral versus subcutaneous fenfluramine administration on rat brain monoamine neurons: Pharmacokinetic and dose-response data

J. Contrera, N. Appel, R. Zaczek, 1991, Pharmacology Biochemistry and Behavior.

Immunohistochemical and Autoradiographic Investigations of High-Dose Fenfluramine Treatment on Monoamine Neurons in Rat Brain

N. Appel, R. Zaczek, E. Souza, 1990 .

Role for brain corticotropin-releasing factor in the weight-reducing effects of chronic fenfluramine treatment in rats.

C. Nemeroff, M. Owens, J. Contrera, 1991, Endocrinology.

Imidazo[4,5-c]pyridines as corticotropin releasing factor receptor ligands.

S. Arneric, R. Olson, D. Robertson, 2003, Bioorganic & medicinal chemistry letters.

The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia

J. Macor, Yulia Benitex, D. Post‐Munson, 2016, PloS one.

Effects of BMS‐902483, an &agr;7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents

Y. Asaka, J. Macor, J. Herrington, 2017, European journal of pharmacology.

MK-801 disrupts and nicotine augments 40 Hz auditory steady state responses in the auditory cortex of the urethane-anesthetized rat

M. Frenkel, N. Lodge, D. V. Sivarao, 2013, Neuropharmacology.

Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity.

C. Albright, D. Barten, J. Meredith, 2006, Drugs in R&D.

Postsynaptic diacylglycerol lipase α mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal cortex

G. González-Burgos, G. Hansen, B. Zambrowicz, 2011, The Journal of physiology.

Quisqualate‐sensitive, chloride‐dependent transport of glutamate into rat brain synaptosomes

J. Coyle, R. Zaczek, M. Balm, 1987, Journal of neuroscience research.

Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat

H. Feldman, J. Macor, R. Berman, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Evidence for a hippocampal-septal glutamatergic pathway in the rat

J. Coyle, J. Hedreen, R. Zaczek, 1979, Experimental Neurology.

Pharmacology of the neurotransmitter release enhancer linopirdine (DuP 996), and insights into its mechanism of action.

B. S. Brown, R. Zaczek, S. Aiken, 1996, Advances in pharmacology.

Studies on the role of K+, Cl- and Na+ ion permeabilities in the acetylcholine release enhancing effects of linopirdine (DuP 996) in rat cortical slices.

J. Saydoff, S. Tam, R. Zaczek, 1994, The Journal of pharmacology and experimental therapeutics.

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor.

J. Macor, C. Albright, R. Olson, 2010, ACS medicinal chemistry letters.

Acetylcholine-releasing agents as cognition enhancers. Structure-activity relationships of pyridinyl pendant groups on selected core structures.

D. Brittelli, R. Earl, M. A. Wuonola, 1992 .

N-acetylaspartylglutamate: an endogenous peptide with high affinity for a brain "glutamate" receptor.

J. Coyle, D. Heller, K. Koller, 1983, Proceedings of the National Academy of Sciences of the United States of America.

Ion channel modulators that enhance acetylcholine release: potential therapies for Alzheimer's disease.

B. S. Brown, R. Zaczek, R. J. Chorvat, 1998, Expert opinion on investigational drugs.

acetylcholine release: potential therapies for Alzheimer's disease

B. S. Brown, R. Zaczek, R. J. Chorvat, 1998 .

8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.

Lawrence Fitzgerald, Ge Zhang, Harvey Wong, 2009, Journal of medicinal chemistry.

6-Hydroxybuspirone Is a Major Active Metabolite of Buspirone: Assessment of Pharmacokinetics and 5-Hydroxytryptamine1A Receptor Occupancy in Rats

R. Taub, H. Wong, R. Dockens, 2007, Drug Metabolism and Disposition.

Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning

J. Macor, Yulia Benitex, R. Olson, 2017, PloS one.

The mechanism of kainic acid neurotoxicity

J. Coyle, J. Ferkany, R. Zaczek, 1984, Nature.

Pharmacological and behavioral characterization of the novel CRF1 antagonist BMS-763534

J. Macor, D. Post‐Munson, T. Molski, 2013, Neuropharmacology.

Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors*

Robert A. Copeland, David W. Robertson, Qian Wang, 2000, The Journal of Biological Chemistry.

Design and synthesis of benzoazepinone-derived cyclic malonamides and aminoamides as potent γ-secretase inhibitors

Michael G. Yang, R. Olson, D. Robertson, 2007 .

The Amyloid-β Rise and γ-Secretase Inhibitor Potency Depend on the Level of Substrate Expression*

Michael G. Yang, J. Macor, M. Ford, 2008, Journal of Biological Chemistry.

N-Acetylaspartylglutamate: possible role as the neurotransmitter of the lateral olfactory tract.

J. Coyle, D. Carpenter, J. ffrench-Mullen, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Acidic peptides in brain: do they act at putative glutamatergic synapses?

J. Coyle, R. Fisher, R. Blakely, 1986, Advances in experimental medicine and biology.

Synthesis and evaluation of succinoyl-caprolactam γ-secretase inhibitors

Marcie A. Glicksman, M. Glicksman, D. Seiffert, 2006 .

Blockade of N- and Q-type Ca2+ channels inhibit K+-evoked [3H]acetylcholine release in rat hippocampal slices

J. Saydoff, R. Zaczek, 1996, Brain Research Bulletin.

Ex Vivo Occupancy of γ-Secretase Inhibitors Correlates with Brain β-Amyloid Peptide Reduction in Tg2576 Mice

C. Albright, R. Olson, J. Toyn, 2007, Journal of Pharmacology and Experimental Therapeutics.

Characterization of brain interactions with methylenedioxyamphetamine and methylenedioxymethamphetamine.

E. D. De Souza, R. Zaczek, S. Culp, 1989, NIDA research monograph.

Intrasynaptosomal Sequestration of [3H]Amphetamine and [3H]Methylenedioxyamphetamine: Characterization Suggests the Presence of a Factor Responsible for Maintaining Sequestration

R. Zaczek, S. Culp, E. Souza, 1990, Journal of neurochemistry.

Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.

D. Robertson, P J Gilligan, D W Robertson, 2000, Journal of medicinal chemistry.

Synthesis and evaluation of candidate PET radioligands for corticotropin-releasing factor type-1 receptors.

M. Imaizumi, S. Zoghbi, V. Pike, 2014, Nuclear medicine and biology.

Local and distant neuronal degeneration following intrastriatal injection of kainic acid.

J. Coyle, R. Zaczek, S. Simonton, 1980, Journal of neuropathology and experimental neurology.

Dipeptides of glutamate and aspartate may be endogenous neuroexcitants in the rat hippocampal slice

J. Coyle, R. Fisher, J. Bernstein, 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

A simple method for quantitative electroencephalographic assessment of drugs with convulsant and anticonvulsant properties

J. Coyle, R. Zaczek, A. Markl, 1986, Journal of Neuroscience Methods.

N-methyl-d-aspartic acid: A convulsant with weak neurotoxic properties

J. Coyle, R. Zaczek, J. Collins, 1981, Neuroscience Letters.

Acetylcholine release enhancers related to linopirdine: A structure—activity relationship study. II*

R. Earl, C. Teleha, R. Zaczek, 1996 .

JPET # 199356 3 Recommended section assignment to guide listing in table of contents : Neuropharmacology

H. Feldman, J. Macor, R. Berman, 2012 .

Phase 1 Clinical Results for NP10679, a pH‐sensitive GluN2B‐selective N‐methyl‐d‐aspartate Receptor Inhibitor

R. Dingledine, S. Traynelis, D. Laskowitz, 2023, Clinical pharmacology in drug development.

Inhibition of AAK 1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain s

Alan G. E. Wilson, Malley, G. Shankar, 2016 .

Characteristics of chloride-dependent incorporation of glutamate into brain membranes argue against a receptor binding site

T. Murphy, J. Coyle, R. Zaczek, 1987, Neuropharmacology.

γ-Secretase activity is not involved in presenilin-mediated regulation of β-catenin ☆

D. Seiffert, R. Olson, A. Stern, 2002 .

Effects of sustained seizures produced by intrahippocampal injection of kainic acid on noradrenergic neurons: evidence for local control of norepinephrine release.

J. Coyle, J T Coyle, R Zaczek, 1980, The Journal of pharmacology and experimental therapeutics.

Brain transcription factor gene expression, neurotransmitter levels, and novelty response behaviors: Alterations during rat amphetamine withdrawal and following chronic injection stress

G. Uhl, A. Persico, C. Schindler, 1995, Synapse.

Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.

Joseph Payne, Vijay T. Ahuja, Yue-Zhong Shu, 2009, Journal of medicinal chemistry.

N-Acetylaspartylglutamate: possible role as the neurotransmitter of the lateral olfactory tract.

J. Coyle, D. Carpenter, J. ffrench-Mullen, 1985, Proceedings of the National Academy of Sciences of the United States of America.

BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.

J. Macor, Yulia Benitex, D. Post‐Munson, 2017, ACS medicinal chemistry letters.

Pharmacological Characterization of a Novel Nonpeptide Antagonist Radioligand, ( (cid:1) ) -N -[2-Methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1 H -1,2,3-triazolo[4,5-c ]pyridin-4-amine ([ 3 H]SN003) for Corticotropin-Releasing Factor 1 Receptors

D. Rominger, Cynthia M. Rominger, R. Zaczek, 2003 .